NIMH/NIH Consensus Development Conference statement. Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel.
This report represents the consensus of a panel of representatives from psychiatry, psychology, pharmacology, epidemiology, internal medicine, and the general public regarding the use of pharmacologic agents to prevent recurrences of mood disorders. The panel concluded that recurrent mood disorders, which have a high prevalence and serious consequences, are underdiagnosed and undertreated. Applying appropriate strategies to the management and use of pharmacologic agents will enhance the likelihood of compliance and the prevention of recurrence with a minimum of bothersome side effects. Such strategies should be used within the context of a supportive relationship among doctor, patient, and family.
D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D003376:Counseling; D003866:Depressive Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D008094:Lithium / Q000009:adverse effects / Q000627:therapeutic use*; D019964:Mood Disorders / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D009315:National Institute of Mental Health (U.S.); D009316:National Institutes of Health (U.S.); D010349:Patient Compliance; D011613:Psychotherapy; D012008:Recurrence; D012306:Risk; D014481:United States
D000929:Antidepressive Agents, Tricyclic; D008094:Lithium